Jeannette Potts Sells 4,781 Shares of uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) insider Jeannette Potts sold 4,781 shares of uniQure stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $4.98, for a total transaction of $23,809.38. Following the completion of the sale, the insider now owns 91,819 shares in the company, valued at $457,258.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $4.57 on Wednesday. The company has a market capitalization of $221.87 million, a price-to-earnings ratio of -0.74 and a beta of 1.08. uniQure has a 12 month low of $4.25 and a 12 month high of $19.63. The firm’s 50-day moving average is $4.87 and its 200 day moving average is $5.60. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The firm had revenue of $8.49 million for the quarter, compared to the consensus estimate of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. Research analysts predict that uniQure will post -4.5 EPS for the current year.

Analyst Upgrades and Downgrades

QURE has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Wednesday, May 8th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Friday, March 1st. The Goldman Sachs Group downgraded shares of uniQure from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $63.00 to $8.00 in a report on Thursday, February 29th. Finally, Mizuho reduced their target price on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.75.

Institutional Investors Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Vestal Point Capital LP purchased a new stake in uniQure in the 4th quarter valued at about $26,572,000. Citigroup Inc. boosted its position in uniQure by 667.9% in the 3rd quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock valued at $5,143,000 after buying an additional 666,696 shares during the period. BNP Paribas Financial Markets boosted its position in uniQure by 173.5% in the 4th quarter. BNP Paribas Financial Markets now owns 706,670 shares of the biotechnology company’s stock valued at $4,784,000 after buying an additional 448,319 shares during the period. abrdn plc purchased a new stake in uniQure in the 4th quarter valued at about $2,711,000. Finally, Bridger Management LLC boosted its position in uniQure by 2,917.3% in the 4th quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock valued at $2,453,000 after buying an additional 350,340 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.